Browsing Tag
Rare diseases
36 posts
From biosimilars to biotech gold: How Momenta scored a $6.5bn exit with J&J
Johnson & Johnson is acquiring Momenta Pharmaceuticals for $6.5 billion to expand its autoimmune pipeline. Find out what makes nipocalimab worth the bet.
August 20, 2020
F2G’s olorofim gets FDA ODD for mold infections and Valley Fever
F2G has bagged orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for olorofim (formerly…
March 12, 2020
Merck acquires ArQule for $2.7bn to further diversify oncology pipeline
Merck acquisition of ArQule : Merck has completed its previously announced acquisition of ArQule for $20 per share…
January 18, 2020
Astellas Pharma to acquire US gene therapy company Audentes Therapeutics
Astellas acquisition of Audentes: Japanese pharma company Astellas Pharma has agreed to acquire US gene therapy company Audentes…
December 8, 2019
Celgene, Acceleron bag Reblozyl FDA approval for anemia in beta thalassemia
Reblozyl FDA approval : Celgene and Acceleron Pharma have bagged approval from the US Food and Drug Administration…
November 9, 2019
Alexion to acquire Achillion to strengthen rare diseases portfolio
Alexion acquisition of Achillion : Alexion Pharmaceuticals has agreed to acquire rival US pharma company Achillion Pharmaceuticals for…
October 17, 2019
Pfizer wraps up $810m acquisition of Swiss biotech company Therachon
Pfizer acquisition of Therachon : US pharma giant Pfizer has completed its previously announced acquisition of Swiss biotech…
July 7, 2019
Biogen to acquire Nightstar Therapeutics in a deal worth $800m to target retinal diseases
In a significant move within the biotech sector, Biogen, the US-based biotechnology giant, has announced its agreement to…
March 31, 2019
X4 Pharmaceuticals completes merger with Arsanis to advance rare disease and cancer treatments
X4 Pharmaceuticals has finalised its merger with Arsanis, creating a late-stage biopharmaceutical company focused on tackling rare diseases…
March 13, 2019
Eusa Pharma completes $115m acquisition of Sylvant for iMCD treatment
Eusa Pharma has successfully acquired the global rights to Sylvant (siltuximab), a drug used in the treatment of…
January 20, 2019